Activating mutations of the calcium-sensing receptor: The calcilytics ATF-936 and AXT-914 attenuate mutants causing autosomal dominant hypocalcemia and Bartter syndrome type 5

MLA

E Schulze, et al. “Activating Mutations of the Calcium-Sensing Receptor: The Calcilytics ATF-936 and AXT-914 Attenuate Mutants Causing Autosomal Dominant Hypocalcemia and Bartter Syndrome Type 5.” Experimental and Clinical Endocrinology & Diabetes, vol. 121, Mar. 2013. EBSCOhost, https://doi.org/10.1055/s-0033-1336667.

APA

E Schulze, Christof Schöfl, S Letz, K. Frank-Raue, F. Raue, B Mayr, & C Haag. (2013). Activating mutations of the calcium-sensing receptor: The calcilytics ATF-936 and AXT-914 attenuate mutants causing autosomal dominant hypocalcemia and Bartter syndrome type 5. Experimental and Clinical Endocrinology & Diabetes, 121. https://doi.org/10.1055/s-0033-1336667

Chicago

E Schulze, Christof Schöfl, S Letz, K. Frank-Raue, F. Raue, B Mayr, and C Haag. 2013. “Activating Mutations of the Calcium-Sensing Receptor: The Calcilytics ATF-936 and AXT-914 Attenuate Mutants Causing Autosomal Dominant Hypocalcemia and Bartter Syndrome Type 5.” Experimental and Clinical Endocrinology & Diabetes 121 (March). doi:10.1055/s-0033-1336667.